Congratulations to James Gern, MD, who recently was awarded a supplement to his U19 grant award from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIH-NIAID) Asthma and Allergic Diseases Cooperative Research Centers (AADCRC). The supplement, in the amount of $143,009, is titled, “A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV-16) Inoculum in Healthy Volunteers,” and will help determine the dose of reverse genetics human rhinovirus 16 (RG-RV16) needed to produce moderate colds in most seronegative individuals, in order lead to testing of new antiviral agents.